Gastric Volume in Patients on GLP-1 Medications
Sponsor
Children's Hospital of Philadelphia (Other)
Overall Status
Recruiting
CT.gov ID
NCT05903482
Collaborator
(none)
90
1
6.8
13.2
Study Details
Study Description
Brief Summary
Evaluating gastric volume in patients on GLP-1 RA medications
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
90 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Gastric Volume in Patients on GLP-1 Medications
Actual Study Start Date
:
Jun 6, 2023
Anticipated Primary Completion Date
:
Dec 31, 2023
Anticipated Study Completion Date
:
Dec 31, 2023
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Diabetic, in GLP-1 RA
|
Other: None - observational
Observational
|
| Diabetic, not on GLP-1 RA
|
Other: None - observational
Observational
|
| Non-diabetic, not on GLP-1 RA
|
Other: None - observational
Observational
|
Outcome Measures
Primary Outcome Measures
- Gastric volume in pediatric patients on GLP-1 RA [single observation]
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Fasting Diabetic On GLP-1 RA
Exclusion Criteria:
Prior surgery that affects gastric anatomy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | United States | 19004 |
Sponsors and Collaborators
- Children's Hospital of Philadelphia
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Elaina Lin,
Attending Physician,
Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier:
NCT05903482
Other Study ID Numbers:
- 23-021125
First Posted:
Jun 15, 2023
Last Update Posted:
Jun 15, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No